Discover 999 paid clinical trials in Rochester, Minnesota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 999
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Rochester MN, Scottsdale AZ
Sponsor: Mayo Clinic
Sex: All
Age: 18+
Code: NCT03516617
Phase 2, Recruiting
MRI-Guided Cryoablation for Focal Native Prostate Cancer
for
Primary Malignant Neoplasm of Prostate (Diagnosis)
Location: Rochester MN
Sponsor: Mayo Clinic
Sex: Male
Age: 30 - 70+
Code: NCT04797039
Recruiting
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
for
AL Amyloidosis
Location: Rochester MN, La Crosse WI, Saint Paul MN, Edina MN,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT06022939
Phase 3, Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
for
B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma,
Location: Rochester MN, Iowa City IA, Detroit MI, Nashville TN,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT05006716
Phase 1, Phase 2, Recruiting
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
Assessing the Effect of Computer-based Auditory Training on Adult Cochlear Implant Speech and Quality-of-life Outcomes
for
Cochlear Implants, Bilateral Sensorineural Hearing Loss
Location: Rochester MN
Sponsor: Mayo Clinic
Sex: All
Age: 18+
Code: NCT06607146
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
for
Oligometastatic Prostate Cancer (OMPC)
Location: Rochester MN, Des Moines IA, Omaha NE, Elk Grove IL,
Sponsor: Novartis Pharmaceuticals
Sex: Male
Age: 18 - 70+
Code: NCT05939414
Phase 3, Recruiting
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
for
Metastatic Colorectal Carcinoma,
Location: Rochester MN, Minneapolis MN, Madison WI, Chicago IL,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 18+
Code: NCT05863195
Phase 3, Recruiting
Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities
for
Breast Neoplasm
Location: Rochester MN
Sponsor: Mayo Clinic
Sex: Female
Age: 18+
Code: NCT06058650
Recruiting
Mechanisms of Anabolic Resistance in Older Humans
for
Aging
Location: Rochester MN
Sponsor: Mayo Clinic
Sex: All
Age: 21 - 70+
Code: NCT06617195
Recruiting
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
for
Primary Hyperoxaluria Type 1 (PH1)
Location: Rochester MN
Sponsor: Arbor Biotechnologies
Sex: All
Age: 6 - 64
Code: NCT06839235
Phase 1, Phase 2, Recruiting
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
for
Autosomal Recessive Polycystic Kidney (ARPKD)
Location: Rochester MN, Ann Arbor MI, Cincinnati OH, Cleveland OH,
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sex: All
Age: 0 - 18
Code: NCT04782258
Phase 3, Recruiting
A Comparison of Neuromuscular Recruitment in Trained and Untrained Adults
for
Healthy, Insulin Resistance
Location: Rochester MN
Sponsor: Mayo Clinic
Sex: All
Age: 60 - 70+
Code: NCT06820658
Recruiting
Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
for
Resistant Hypertension
Location: Rochester MN, Detroit MI, Atlanta GA, Gainesville FL,
Sponsor: DeepQure Inc.
Sex: All
Age: 22 - 70+
Code: NCT06526858
Recruiting
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma